Apolipoprotein E, Amyloid-β, and Blood-Brain Barrier Permeability in Alzheimer Disease
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
There is increasing evidence for blood-brain barrier (BBB) compromise in Alzheimer disease (AD). The presence of the epsilon4 allele of the apolipoprotein E (apoE) gene is a risk factor for sporadic AD. Apolipoprotein E is essential both for maintenance of BBB integrity and for the deposition of fibrillar amyloid-beta (Abeta) that leads to the development of Abeta plaques in AD and to cerebral amyloid angiopathy. This review investigates the relationships between apoE, Abeta, and the BBB in AD. Alterations in the expression and distribution of the BBB Abeta transporters receptor for advanced glycation end-products and low-density lipoprotein receptor-related protein 1 in AD and the potential roles of apoE4 expression in adversely influencing Abeta burden and BBB permeability are also examined. Because both apoE and Abeta are ligands for low-density lipoprotein receptor-related protein 1, all 3 molecules are present in AD plaques, and most AD plaques are located close to the cerebral microvasculature. The interactions of these molecules at the BBB likely influence metabolism and clearance of Abeta and contribute to AD pathogenesis. Therapeutic alternatives targeting apoE/Abeta and sealing a compromised BBB are under development for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 12×
“The ZO proteins link the integral membrane proteins of the tight junction to the underlying cytoskeleton and bind to signaling molecules such as transcription factors during cellular states of stress and proliferation; they also act as signaling molecules that communicate the condition of the tight junction to the int…”
BackgroundInfluentialRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 3×
“Two of the bettercharacterized receptors are the receptor for advanced glycation end-products (RAGE) (37) and the low-density LRP-1 (38).”
BackgroundHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · cited 5×
“However, these P-gp KO APP mice also have reduced vascular expression of LRP-1 (39), and another study suggests that the contribution of P-gp to AA extrusion from the brain may be minimal (47).”
BackgroundInfluentialRAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519 · cited 2×
“Moreover, apoE, LRP-1, and AA colocalize within AD senile plaques (48), and LRP-1 is downregulated on the cerebral microvasculature in severe AD cases, reducing AA transport out of the brain (48).”
BackgroundSelf-citationApolipoprotein E and Alzheimer's disease
Strittmatter, W. J., & Roses, A. D. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.19.030196.000413 · Cited by 477
Identification of agrin, a synaptic organizing protein from Torpedo electric organ.
Nitkin, R. M., Smith, M. A., Magill, C., Fallon, J. R., Yao, Y. M., Wallace, B. G., & McMahan, U. J. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.6.2471 · Cited by 469 · cited 1×
“Agrin is a multidomain heparan sulfate proteoglycan that was initially discovered to be crucial for the normal development of the neuromuscular junction and peripheral synaptogenesis because it causes acetylcholine receptors to aggregate at the postsynaptic membrane, hence the name (62).”
BackgroundD'Andrea, M. R., Nagele, R. G., Wang, H., Peterson, P. A., & Lee, D. H. S. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01082.x · Cited by 390
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., et al. (2000) · Nature Medicine · doi:10.1038/76216 · Cited by 343 · cited 1×
“It binds a wide range of molecules, including the products of nonenzymatic glycoxidation (advanced glycation end-products), AA, proinflammatory cytokine-like mediators in the S-100/calgranulin family, and a DNA-binding protein, amphoterin (41).”
BackgroundClearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Fryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278 · cited 9×
“Another study demonstrated that, although clearance of exogenous, intraventricularly injected AA1-42 from the CSF into the systemic circulation was much slower than clearance of injected AA1-40 (and may depend more on catabolic pathways than transport across the BBB), the elimination rate of both AA1-40 and AA1-42 was…”
BackgroundInfluentialMackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242 · cited 1×
“Although some systemic AA may enter the brain passively via a leaky BBB (14), active transport of AA across the BBB also occurs (34), using a number of AA receptors (35, 36).”
BackgroundHuman apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.
Weisgraber, K. H., Rall, S. C., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35898-2 · Cited by 240
Lalazar (1989) · doi:10.1016/s0021-9258(18)81806-3 · Cited by 238
Dodart, J.-C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., & Paul, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409072102 · Cited by 207
Ruiz, J., Kouiavskaia, D., Migliorini, M., Robinson, S., Saenko, E. L., Gorlatova, N., Li, D., Lawrence, D., Hyman, B. T., Weisgraber, K. H., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500114-jlr200 · Cited by 204 · cited 2×
“Another study demonstrated that, although clearance of exogenous, intraventricularly injected AA1-42 from the CSF into the systemic circulation was much slower than clearance of injected AA1-40 (and may depend more on catabolic pathways than transport across the BBB), the elimination rate of both AA1-40 and AA1-42 was…”
BackgroundSadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167 · cited 3×
“A number of therapeutic alternatives to seal a compromised BBB and eliminate AA deposits have been tested in transgenic AD mouse models, including AA vaccination without significant inflammation or hemorrhage (73), gene delivery of human apoE2 (74), blocking the apoE/AA interaction with a synthetic AA peptide (75), an…”
BackgroundMethodChalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149 · cited 1×
“AA Deposition and ApoE Studies have shown that apoE4 results in increased deposition of AA1-40 within the brain parenchyma (53), an increased ratio of AA1-40YAA1-42 in brain extracellular pools (11), and enhanced vascular sequestration and brain uptake of soluble AA1-40 complexed with apoE4 (as compared with apoE2 and…”
BackgroundApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage
Hafezi-Moghadam, A., Thomas, K. L., & Wagner, D. D. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00563.2005 · Cited by 149 · cited 3×
“Moreover, this BBB permeability increases as these apoE KO mice age (59).”
BackgroundCummings, B. J., Su, J. H., Geddes, J. W., Van Nostrand, W. E., Wagner, S. L., Cunningham, D. D., & Cotman, C. W. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90265-4 · Cited by 120
Impairment of the Blood–Nerve and Blood–Brain Barriers in Apolipoprotein E Knockout Mice
Fullerton, S. M., Shirman, G. A., Strittmatter, W. J., & Matthew, W. D. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7631 · Cited by 117 · cited 6×
“Apolipoprotein E might also alter BBB permeability by altering transport mechanisms at the level of the endothelial cell (58).”
BackgroundInfluentialEffect of APOE genotype on microvascular basement membrane in Alzheimer's disease
Salloway, S., Gur, T., Berzin, T., Zipser, B., Correia, S., Hovanesian, V, Fallon, J., Kuo-Leblanc, V, Glass, D., Hulette, C., et al. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00288-5 · Cited by 113 · cited 2×
“Agrin, ApoE Genotype, and Microvascular Surface Area Another study demonstrated the relationship between apoE genotype and capillary basement membrane surface area, as measured by anti-agrin immunoreactivity (66).”
BackgroundAβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
Dickstein, D. L., Biron, K. E., Ujiie, M., Pfeifer, C. G., Jeffries, A. R., & Jefferies, W. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-3956com · Cited by 111 · cited 6×
“Proposed mechanisms include increased microgliosis with its associated inflammatory mediators and cytokines, and alterations of the tight junctions induced by proapoptotic and proangiogenic responses in the endothelial cells mediated by AA (50).”
BackgroundInfluentialMonro, O. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00317-7 · Cited by 107
Sabo, T., Lomnitski, L., Nyska, A., Beni, S., Maronpot, R. R., Shohami, E., Roses, A. D., & Michaelson, D. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00438-3 · Cited by 104 · cited 1×
“Apolipoprotein E4 has also been shown to be a risk factor for atherosclerosis (6), stroke (7, 8), prolonged recovery from closed head injury (9), and increased mortality from intracerebral hemorrhage (8).”
BackgroundMann, D. M. A., Iwatsubo, T., Pickering-Brown, S. M., Owen, F., Saido, T. C., & Perry, R. H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13294-8 · Cited by 91
Cited by
Janssen, C. I. F., & Kiliaan, A. J. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.10.002 · Cited by 514
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Healthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 292
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“Decreased BBB permeability could potentially lead to increased deposition of Ab within AD brains (Bachmeier et al. 2010; Donahue and Johanson 2008; Liu et al. 2009a).”
BackgroundClearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Metadata
- Authors
- Donahue, J. E., & Johanson, C. E.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04
- Volume
- 67
- Issue
- 4
- Pages
- 261-270
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2053091943
- Cited by
- 86
- References
- 30
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.